NASDAQ:MDGL Madrigal Pharmaceuticals (MDGL) Stock Price, News & Analysis → Reclusive millionaire’s final warning about America (From Weiss Ratings) (Ad) Free MDGL Stock Alerts $276.01 -0.71 (-0.26%) (As of 04:27 PM ET) Add Compare Share Share Today's Range$273.28▼$279.2650-Day Range$193.33▼$291.9952-Week Range$119.76▼$299.98Volume308,333 shsAverage Volume526,820 shsMarket Capitalization$5.88 billionP/E RatioN/ADividend YieldN/APrice Target$348.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Madrigal Pharmaceuticals alerts: Email Address Madrigal Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside26.1% Upside$348.17 Price TargetShort InterestBearish24.54% of Shares Sold ShortDividend StrengthN/ASustainability-0.92Upright™ Environmental ScoreNews Sentiment0.67Based on 16 Articles This WeekInsider TradingSelling Shares$36.96 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($27.62) to ($17.59) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.51 out of 5 starsMedical Sector85th out of 913 stocksPharmaceutical Preparations Industry29th out of 430 stocks 4.4 Analyst's Opinion Consensus RatingMadrigal Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 10 buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageMadrigal Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Madrigal Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted24.54% of the outstanding shares of Madrigal Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverMadrigal Pharmaceuticals has a short interest ratio ("days to cover") of 9.4.Change versus previous monthShort interest in Madrigal Pharmaceuticals has recently increased by 25.42%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMadrigal Pharmaceuticals does not currently pay a dividend.Dividend GrowthMadrigal Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMadrigal Pharmaceuticals has received a 73.28% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Madrigal Pharmaceuticals is -0.92. Previous Next 2.0 News and Social Media Coverage News SentimentMadrigal Pharmaceuticals has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Madrigal Pharmaceuticals this week, compared to 6 articles on an average week.Search InterestOnly 10 people have searched for MDGL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 9 people have added Madrigal Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Madrigal Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $36,959,547.00 in company stock.Percentage Held by Insiders23.92% of the stock of Madrigal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions98.50% of the stock of Madrigal Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Madrigal Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Madrigal Pharmaceuticals are expected to grow in the coming year, from ($27.62) to ($17.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Madrigal Pharmaceuticals is -11.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Madrigal Pharmaceuticals is -11.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMadrigal Pharmaceuticals has a P/B Ratio of 13.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Madrigal Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyKiss of death from Joe BidenBiden cannot lose this election. A bombshell new documentary exposes how the D.C establishment has engineered an “electoral failsafe” that all but guarantees Democratic victory… not just in 2024 but every future election.I have uncovered a bombshell that changes everything… and threatens everything. About Madrigal Pharmaceuticals Stock (NASDAQ:MDGL)Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.Read More MDGL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MDGL Stock News HeadlinesJune 15 at 8:46 AM | insidertrades.comInsider Selling: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) VP Sells 2,000 Shares of StockMay 24, 2024 | insidertrades.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) VP Robert E. Waltermire Sells 1,036 SharesJune 18, 2024 | Paradigm Press (Ad)Musk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840.May 18, 2024 | insidertrades.comFred B. Craves Sells 22,489 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) StockJune 16 at 12:05 PM | fool.comThinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word.June 16 at 5:08 AM | americanbankingnews.comRobert E. Waltermire Sells 2,000 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) StockJune 15 at 9:45 AM | fool.comWhere Will Madrigal Pharmaceuticals Be in 3 Years?June 13, 2024 | americanbankingnews.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Shares Up 1.8%June 18, 2024 | Paradigm Press (Ad)Musk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840.June 12, 2024 | seekingalpha.comMadrigal Pharmaceuticals: The GLP-1 Threat May Be OvercookedJune 12, 2024 | americanbankingnews.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Coverage Initiated by Analysts at Wolfe ResearchJune 10, 2024 | fool.comBetter Biotech Stock: Viking Therapeutics vs. Madrigal PharmaceuticalsJune 9, 2024 | seekingalpha.comMadrigal May Not Be Able To Shrug GLP-1 Drugs For LongJune 8, 2024 | americanbankingnews.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Trading Down 3.9%June 6, 2024 | globenewswire.comMadrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL CongressMay 29, 2024 | finance.yahoo.comMadrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL CongressMay 24, 2024 | finance.yahoo.comInsider Sale at Madrigal Pharmaceuticals Inc (MDGL): Senior VP, Chief Pharmaceutical ...May 21, 2024 | fool.comIs Madrigal Pharmaceuticals Stock a Buy?May 20, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Immunocore Holdings (IMCR) and Madrigal Pharmaceuticals (MDGL)May 15, 2024 | finance.yahoo.comJohn Paulson's Strategic Moves in Q1 2024 Highlight Madrigal Pharmaceuticals' Prominent RoleMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Madrigal Pharmaceuticals Amid Strong Start for RezdiffraMay 8, 2024 | markets.businessinsider.comMadrigal Pharmaceuticals: Strong Buy Rating Amidst Rapid Growth and Strategic InitiativesMay 8, 2024 | benzinga.comSpotlight on Madrigal Pharmaceuticals: Analyzing the Surge in Options ActivityMay 8, 2024 | finance.yahoo.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2024 Earnings Call TranscriptMay 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Madrigal Pharmaceuticals Amid Promising Launch of First Approved NASH Treatment and Strong Market PositioningMay 8, 2024 | finance.yahoo.comMadrigal Pharmaceuticals Inc (MDGL) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...May 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Madrigal Pharmaceuticals Amid Strong Rezdiffra Launch and Solid FinancialsSee More Headlines Receive MDGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today6/18/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:MDGL CUSIP87162T20 CIK1157601 Webwww.madrigalpharma.com Phone(267) 824-2827Fax781-274-8228Employees376Year Founded2011Price Target and Rating Average Stock Price Target$348.17 High Stock Price Target$410.00 Low Stock Price Target$150.00 Potential Upside/Downside+25.8%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($23.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-373,630,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-128.60% Return on Assets-78.52% Debt Debt-to-Equity Ratio0.14 Current Ratio9.39 Quick Ratio9.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$20.53 per share Price / Book13.48Miscellaneous Outstanding Shares21,310,000Free Float16,214,000Market Cap$5.90 billion OptionableOptionable Beta-0.41 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Rebecca A. Taub M.D. (Age 72)Founder, Chief Medical Officer, President of Research & Development and Director Comp: $939.83kMr. Brian J. Lynch J.D. (Age 62)Senior VP & General Counsel Comp: $763.75kMr. Alex G. Howarth (Age 55)Executive Officer Comp: $757.26kMr. William J. Sibold (Age 58)CEO, President & Director Ms. Mardi C. Dier (Age 60)CFO, Principal Financial Officer, Principal Accounting Officer & Senior VP Mr. Ronald FilippoChief Information OfficerMs. Tina E. VenturaChief Investor Relations OfficerDr. Kianoush Motesharei Ph.d. (Age 54)Senior Vice President of Business & Corporate Development Mr. Clint WallaceChief Human Resources OfficerMr. Edward ChiangSenior Vice President of Clinical & Technical OperationsMore ExecutivesKey CompetitorsDicerna PharmaceuticalsNASDAQ:DRNARocket PharmaceuticalsNASDAQ:RCKTIntercept PharmaceuticalsNASDAQ:ICPTY-mAbs TherapeuticsNASDAQ:YMABGeneration BioNASDAQ:GBIOView All CompetitorsInsiders & InstitutionsRobert E WaltermireSold 2,000 sharesTotal: $570,000.00 ($285.00/share)EULAV Asset ManagementSold 2,000 shares on 5/30/2024Ownership: 0.052%Verity Asset Management Inc.Sold 1,115 shares on 5/28/2024Ownership: 0.007%Cetera Advisors LLCBought 1,051 shares on 5/24/2024Ownership: 0.005%Robert E WaltermireSold 1,036 sharesTotal: $239,668.24 ($231.34/share)View All Insider TransactionsView All Institutional Transactions MDGL Stock Analysis - Frequently Asked Questions Should I buy or sell Madrigal Pharmaceuticals stock right now? 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MDGL shares. View MDGL analyst ratings or view top-rated stocks. What is Madrigal Pharmaceuticals' stock price target for 2024? 12 brokerages have issued 1 year price targets for Madrigal Pharmaceuticals' stock. Their MDGL share price targets range from $150.00 to $410.00. On average, they expect the company's share price to reach $348.17 in the next twelve months. This suggests a possible upside of 26.1% from the stock's current price. View analysts price targets for MDGL or view top-rated stocks among Wall Street analysts. How have MDGL shares performed in 2024? Madrigal Pharmaceuticals' stock was trading at $231.38 at the beginning of the year. Since then, MDGL stock has increased by 19.3% and is now trading at $276.01. View the best growth stocks for 2024 here. Are investors shorting Madrigal Pharmaceuticals? Madrigal Pharmaceuticals saw a increase in short interest during the month of May. As of May 31st, there was short interest totaling 5,230,000 shares, an increase of 25.4% from the May 15th total of 4,170,000 shares. Based on an average daily volume of 556,400 shares, the days-to-cover ratio is presently 9.4 days. View Madrigal Pharmaceuticals' Short Interest. When is Madrigal Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our MDGL earnings forecast. How were Madrigal Pharmaceuticals' earnings last quarter? Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) issued its quarterly earnings results on Tuesday, May, 7th. The biopharmaceutical company reported ($7.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($6.06) by $1.32. During the same quarter last year, the company earned ($4.23) earnings per share. What ETFs hold Madrigal Pharmaceuticals' stock? ETFs with the largest weight of Madrigal Pharmaceuticals (NASDAQ:MDGL) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Tema Cardiovascular and Metabolics ETF (HRTS), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Biotechnology ETF (IBBQ) and iShares Biotechnology ETF (IBB). What other stocks do shareholders of Madrigal Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Madrigal Pharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Exelixis (EXEL), Ayala Pharmaceuticals (ADXS), Viking Therapeutics (VKTX), Sangamo Therapeutics (SGMO), Amarin (AMRN), CRISPR Therapeutics (CRSP), Intercept Pharmaceuticals (ICPT), Sarepta Therapeutics (SRPT) and Gilead Sciences (gild). Who are Madrigal Pharmaceuticals' major shareholders? Madrigal Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Janus Henderson Group PLC (12.21%), Avoro Capital Advisors LLC (9.12%), Vanguard Group Inc. (7.84%), Price T Rowe Associates Inc. MD (3.77%), Jane Street Group LLC (0.00%) and Bain Capital Life Sciences Investors LLC (0.92%). Insiders that own company stock include Brian Joseph Lynch, Bros Advisors Lp Baker, Fred B Craves, James M Daly, Paul A Friedman, Rebecca Taub, Remy Sukhija, Richard S Levy and Robert E Waltermire. View institutional ownership trends. How do I buy shares of Madrigal Pharmaceuticals? Shares of MDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MDGL) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | Sponsoredwhy 99.94% won’t make you moneyI believe there's only 5-7 stocks that you should trade in 2024. But here's the catch…because there's alway...Prosper Trading Academy | SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredExecutive Order To Wipe Out Your Bank AccountsDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Madrigal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Madrigal Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.